Clinical Trials in China / NCT07532928
Enrolling by invitation
Observational
A Bidirectional Study of Individualized Postoperative Adjuvant Treatment Decision Model for Locally Advanced Head and Neck Squamous Cell Carcinoma Based on Multimodal Dynamic Data
NCT07532928 · tracked via the Priya Life Science China tracker
Condition(s) studied
Deep LearningHead & Neck Squamous Cell Carcinoma
Study summary
Based on multimodal data, the investigators establish a dynamic deep learning model to conduct prognostic risk assessment for patients and recommend the 'most suitable' treatment/follow-up regimen after radical treatment, assisting clinicians in improving homogenized evaluation levels and achieving individualized precision therapy, thereby providing scientific evidence for the currently widely debated selection of postoperative adjuvant therapy in locally advanced head and neck squamous cell carcinoma patients.
Eligibility
Inclusion Criteria:
* Age \>= 18 years.
* Patients diagnosed and treated at Nanfang Hospital, Southern Medical University or its cooperative hospitals between January 2017 and December 2025.
* Patients who either seek medical treatment after June 2022 or sought medical treatment before that but have not lost contact with the hospital for more than 1 year are required to sign the informed consent form voluntarily.
* Newly diagnosed head and neck squamous cell carcinoma (HNSCC) confirmed by histopathology.
* Locally advanced disease without distant metastasis.
* Complete clinical data (including patient demographics, tumor characteristics, treatment details, and prognostic variables).
* Availability of MRI, CT, or PET-CT images before and after radical treatment.
Exclusion Criteria:
* History of or coexisting secondary malignancies.
* Lack of definitive radical treatment.
* Absence of baseline or follow-up imaging (MRI/CT/PET-CT).
* Investigator-determined unsuitability for study participation.
Primary outcome measure(s)
- 2-year progress-free survival — 2 years
From the initiation of treatment to the date of tumor progression (including local recurrence, regional lymph node metastasis, and distant metastasis) or tumor-related death, whichever occurs first. If no progression event was observed by the cutoff date of follow-up, the last follow-up date was used.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Department of Radiation Oncology, Nanfang Hospital, Southern Medical University | Guangzhou | China |
More Nanfang Hospital, Southern Medical University trials in China
Other trials for the same condition
Artificial Intelligence in Detecting Cardiac Function
Enrolling by invitation
CT and Endoscopic Biopsy Image-Based Deep Learning for Predicting Left Recurrent Laryngeal Nerve Lymph Node Metastasis in Esophageal Cancer
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07532928 on ClinicalTrials.gov ↗ ← All trials in China